LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...
A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around vascular-mediated functional ...
Serum pharmacoproteomics of erlotinib-treated advanced prostate cancer patients: A SELDI-TOF mass spectrometry analysis No significant financial relationships to disclose. This is an ASCO Meeting ...
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MILAN — A basket study of a new topical ...
DelveInsight's PDE4 Inhibitor Market Report Reveals Significant Growth Through 2034, Led by Arcutis Biotherapeutics, Pfizer, Shionogi, Palisade Bio, UNION Therapeutics, Amgen, and Chiesi Farmaceutici ...
Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.
SAN FRANCISCO -- Patients with idiopathic pulmonary fibrosis (IPF) had no disease progression when they took a novel agent targeting phosphodiesterase (PDE) 4B in a short-term study, researchers ...
May 25, 2006 — Three new studies presented here at the 2006 annual meeting of the American Urological Association support the use of phosphodiesterase-5 (PDE-5) inhibitors for the resolution of lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results